FORM 8 (OPD) – Allergy Therapeutics plc

Allergy Therapeutics PLC
21 April 2023
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Full name of discloser:

Allergy Therapeutics plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

     The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Allergy Therapeutics plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

     The latest practicable date prior to the disclosure

21 April 2023

(f)  In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

     If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2.         POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Ordinary shares of 0.1p each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

 

Nil

 

(2) Cash-settled derivatives:

 

Nil

 

Nil

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

 

Nil

 

 

     TOTAL:

Nil

 

Nil

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b)        Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3.         POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a)   Interests in ordinary shares held by directors of Allergy Therapeutics plc:

 

Name

Number of Ordinary Shares

% of Issued Share Capital

Manuel Llobet

3,325,000

0.48

Peter Jensen

300,000

0.04

Anthony Parker

275,000

0.04

Tunde Otulana

50,000

0.00

 

 

b)   Rights to subscribe for ordinary shares by directors of Allergy Therapeutics plc:

 

Name

Plan name

Grant date

Vesting date

Expiry date

No. of shares under option

Exercise price per share (£)

Manuel Llobet

Share option plan 11a

30/12/2016

27/03/2020

26/03/2030

211,250

0.001

Manuel Llobet

Share option plan 11b

30/12/2016

27/03/2020

26/03/2030

211,250

0.001

Manuel Llobet

Share option plan 12

15/03/2018

30/03/2021

29/03/2031

450,000

0.001

Manuel Llobet

Share option plan 13

01/11/2018

22/11/2021

21/11/2031

803,700

0.001

Manuel Llobet

Conditional option plan 14

27/03/2020

31/05/2023

10 years from vesting (if vested)

900,000

0.001

Manuel Llobet

Conditional option plan 15

22/11/2020

22/11/2023

10 years from vesting (if vested)

900,000

0.001

Manuel Llobet

Conditional option plan 16

22/11/2021

22/11/2024

10 years from vesting (if vested)

900,000

0.001

 

 

 

 

 

c)   Interests held by other presumed concert parties of Allergy Therapeutics plc

 

Name

Number of Ordinary Shares

% of Issued Share Capital

Stephen Smith*

776,513

0.11

 

*Steve Smith, former board member and retained strategic adviser to Allergy Therapeutics plc.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c)        Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

Yes

 

 

Date of disclosure:

21 April 2023

Contact name:

Karley Cheesman, Company secretary

Telephone number:

+44 (0)1903 844 700

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

 

SUPPLEMENTAL FORM 8 (SBL)

 

DETAILS OF SECURITIES BORROWING AND LENDING AND

FINANCIAL COLLATERAL ARRANGEMENTS BY

PARTIES TO AN OFFER AND PERSONS ACTING IN CONCERT

Note 5(l) on Rule 8 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

Full name of person making disclosure:

Manuel Llobet

Name of offeror/offeree in relation to whose relevant securities this form relates:

Allergy Therapeutics plc

 

 

2.         SECURITIES BORROWING AND LENDING/FINANCIAL COLLATERAL POSITIONS

 

Class of relevant security:

 

Ordinary shares of 0.1p each

 

Number

 

%

Securities borrowed:

n/a

 

 

Securities lent (including securities subject to a security financial collateral arrangement with right of use or a title transfer collateral arrangement):

1,725,000

 

 

0.25

 

Details of borrowed relevant securities which have been either on-lent or sold do not need to be disclosed.

 

3.         SECURITIES BORROWING AND LENDING/FINANCIAL COLLATERAL TRANSACTIONS

 

Class of relevant security

Nature of transaction

e.g. securities lending/borrowing, delivery/receipt of recalled securities, entering into financial collateral arrangement with right of use, entering into title transfer collateral arrangement etc.

Number of securities

Ordinary shares of 0.1 pence each

a personal loan agreement on 26 March 2021, whereby security over 600,000 ordinary shares of 0.1 pence each in the capital of the Company was granted in favour of Banco Santander.*

 

600,000

 

Ordinary shares of 0.1 pence each

a personal loan agreement on 9 March 2021, whereby security over 1,125,000 ordinary shares of 0.1 pence each in the capital of the Company was granted in favour of Banco Santander.**

 

1,125,000

 

*Announced 26 March 2021

**Announced 11 March 2021

 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings